Carl Zeiss Meditec (ETR:AFX) Stock Upgrade
DZ-Bank AG has decided to issue a report indicating that Carl Zeiss Meditec (ETR:AFX) shares are now a ‘Buy’ in recent note shared with investors on 19 December.
From a total of 7 analysts covering Carl Zeiss Meditec (ETR:AFX) stock, 4 rate it a ”Buy”, 1 a “Sell”, and 2 a ”Hold”. This means that 57% of the ratings are positive. The highest target price is €29 while the lowest target price is €19.80. The mean of all analyst targets is €26.29 with a -10.27% below today’s (€29.3) stock price. Carl Zeiss Meditec was the topic of 10 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Jefferies downgraded shares on December 17 to “Underperform” rating. Independent Research maintained shares with “Hold” rating and €26 target share price in a report from an August 12. Landesbank upgraded AFX stock in a recent report from October 13 to “Buy” rating. Kepler Cheuvreux upgraded the rating on August 7. Kepler Cheuvreux has a “Buy” rating and a €28 price target on shares. Finally, Berenberg upgraded the stock to “Buy” rating in a report issued on a September 15.
The stock increased 7.03% or EUR 1.92 on December 18, striking EUR 29.3. Approximately 128,936 shares of stock traded hands or 211.11% up from the average. Carl Zeiss Meditec AG (ETR:AFX) has declined 6.80% since May 22, 2015 and is downtrending. It has underperformed by 2.99% the S&P500.
Carl Zeiss Meditec AG is a Germany-based medical technology solutions supplier. The company has a market cap of 2.38 billion EUR. The Firm operates, along with its subsidiaries, in two business areas: Ophthalmology and Microsurgery. It has 34.38 P/E ratio. The Ophthalmology business area is subdivided into two business units: the Ophthalmology systems unit covers a range of laser and diagnostic systems for ophthalmology, and the Surgical Ophthalmology unit combines the Company’s activities in the field of ophthalmic implants and disposables.